Furthermore, the largest and most current systematic review showed that GLP-1 agonists reduced all cause and CV mortality, myocardial infarction, non-fatal stroke, kidney failure and admission for HF in subjects with T2DM [67]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.